Cargando…

Acquired resistance to anti-EGFR mAb ICR62 in cancer cells is accompanied by an increased EGFR expression, HER-2/HER-3 signalling and sensitivity to pan HER blockers

BACKGROUND: The human epidermal growth factor receptor (EGFR) is an important target for cancer treatment. Currently, only the EGFR antibodies cetuximab and panitumumab are approved for the treatment of patients with colorectal cancer. However, a major clinical challenge is a short-term response owi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Khelwatty, Said A, Essapen, Sharadah, Seddon, Alan M, Fan, Zhen, Modjtahedi, Helmout
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2015
Materias:	Translational Therapeutics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4651123/ https://www.ncbi.nlm.nih.gov/pubmed/26372697 http://dx.doi.org/10.1038/bjc.2015.319

Ejemplares similares

Immunohistochemical discrimination of wild-type EGFR from EGFRvIII in fixed tumour specimens using anti-EGFR mAbs ICR9 and ICR10
por: Modjtahedi, H, et al.
Publicado: (2012)

HER2 Expression Is Predictive of Survival in Cetuximab Treated Patients with RAS Wild Type Metastatic Colorectal Cancer
por: Khelwatty, Said A., et al.
Publicado: (2021)

Co-Expression of HER Family Members in Patients with Dukes’ C and D Colon Cancer and Their Impacts on Patient Prognosis and Survival
por: Khelwatty, Said Abdullah, et al.
Publicado: (2014)

The impact of co-expression of wild-type EGFR and its ligands determined by immunohistochemistry for response to treatment with cetuximab in patients with metastatic colorectal cancer
por: Khelwatty, Said, et al.
Publicado: (2016)

Co-expression and prognostic significance of the HER family members, EGFRvIII, c-MET, CD44 in patients with ovarian cancer
por: Puvanenthiran, Soozana, et al.
Publicado: (2018)

Co-expression and prognostic significance of putative CSC markers CD44, CD133, wild-type EGFR and EGFRvIII in metastatic colorectal cancer
por: Khelwatty, Said Abdullah, et al.
Publicado: (2019)

Impact of the putative cancer stem cell markers and growth factor receptor expression on the sensitivity of ovarian cancer cells to treatment with various forms of small molecule tyrosine kinase inhibitors and cytotoxic drugs
por: Puvanenthiran, Soozana, et al.
Publicado: (2016)

Acquired resistance of pancreatic cancer cells to treatment with gemcitabine and HER-inhibitors is accompanied by increased sensitivity to STAT3 inhibition
por: IOANNOU, NIKOLAOS, et al.
Publicado: (2016)

Prognostic and predictive values of EGFR overexpression and EGFR copy number alteration in HER2-positive breast cancer
por: Lee, H J, et al.
Publicado: (2015)

HER2 expression as a potential marker for response to therapy targeted to the EGFR
por: Emlet, D R, et al.
Publicado: (2006)

EGFR inhibitors augment antitumour helper T-cell responses of HER family-specific immunotherapy
por: Kumai, T, et al.
Publicado: (2013)

Targeting EGFR and HER-2 with cetuximab- and trastuzumab-mediated immunotherapy in oesophageal squamous cell carcinoma
por: Kawaguchi, Y, et al.
Publicado: (2007)

Treatment with a combination of the ErbB (HER) family blocker afatinib and the IGF-IR inhibitor, NVP-AEW541 induces synergistic growth inhibition of human pancreatic cancer cells
por: Ioannou, Nikolaos, et al.
Publicado: (2013)

EGFR/HER2 inhibitor AEE788 increases ER-mediated transcription in HER2/ER-positive breast cancer cells but functions synergistically with endocrine therapy
por: Evans, A H, et al.
Publicado: (2010)

Cytogenetic analysis of HER1/EGFR, HER2, HER3 and HER4 in 278 breast cancer patients
por: Sassen, Andrea, et al.
Publicado: (2008)

Novel agents that downregulate EGFR, HER2, and HER3 in parallel
por: Ferreira, Renan Barroso, et al.
Publicado: (2015)

Activity of lapatinib a novel HER2 and EGFR dual kinase inhibitor in human endometrial cancer cells
por: Konecny, G E, et al.
Publicado: (2008)

Model-Based Analysis of HER Activation in Cells Co-Expressing EGFR, HER2 and HER3
por: Shankaran, Harish, et al.
Publicado: (2013)

Synergistic effects of various Her inhibitors in combination with IGF-1R, C-MET and Src targeting agents in breast cancer cell lines
por: Stanley, Aryan, et al.
Publicado: (2017)

Structure and dynamics of the EGFR/HER2 heterodimer
por: Bai, Xue, et al.
Publicado: (2023)

HER2 gene amplification and EGFR expression in a large cohort of surgically staged patients with nonendometrioid (type II) endometrial cancer
por: Konecny, G E, et al.
Publicado: (2009)

Lapatinib, a Dual EGFR and HER2 Tyrosine Kinase Inhibitor, Downregulates Thymidylate Synthase by Inhibiting the Nuclear Translocation of EGFR and HER2
por: Kim, Hwang-Phill, et al.
Publicado: (2009)

Inverse Regulation of EGFR/HER1 and HER2-4 in Normal and Malignant Human Breast Tissue
por: Flågeng, Marianne Hauglid, et al.
Publicado: (2013)

Association of constitutively activated hepatocyte growth factor receptor (Met) with resistance to a dual EGFR/Her2 inhibitor in non-small-cell lung cancer cells
por: Agarwal, S, et al.
Publicado: (2009)

Assessment and prognostic analysis of EGFR, HER2, and HER3 protein expression in surgically resected gastric adenocarcinomas
por: Tang, Daoqiang, et al.
Publicado: (2014)

Notch-EGFR/HER2 Bidirectional Crosstalk in Breast Cancer
por: Baker, Andrew T., et al.
Publicado: (2014)

EGFR Expression in HER2-Driven Breast Cancer Cells
por: Weinberg, Florian, et al.
Publicado: (2020)

Anti-HER2 mAb plus calicheamicin immunoconjugate linked on liposomal vinorelbine induces ADCC and apoptosis in HER2-positive high grade DCIS
por: Giannos, J, et al.
Publicado: (2000)

Protein tyrosine phosphatase SHP-1 sensitizes EGFR/HER-2 positive breast cancer cells to trastuzumab through modulating phosphorylation of EGFR and HER-2
por: Wu, Yifen, et al.
Publicado: (2015)

The pan-HER family tyrosine kinase inhibitor afatinib overcomes HER3 ligand heregulin-mediated resistance to EGFR inhibitors in non-small cell lung cancer
por: Yonesaka, Kimio, et al.
Publicado: (2015)

Phase I trial and tumour localisation of the anti-EGFR monoclonal antibody ICR62 in head and neck or lung cancer.
por: Modjtahedi, H., et al.
Publicado: (1996)

HER2 and HER3 cooperatively regulate cancer cell growth and determine sensitivity to the novel investigational EGFR/HER2 kinase inhibitor TAK-285
por: Takagi, Shinji, et al.
Publicado: (2014)

TAS2940, a novel brain‐penetrable pan‐ERBB inhibitor, for tumors with HER2 and EGFR aberrations
por: Oguchi, Kei, et al.
Publicado: (2022)

Reciprocal Regulation of Annexin A2 and EGFR with Her-2 in Her-2 Negative and Herceptin-Resistant Breast Cancer
por: Shetty, Praveenkumar K., et al.
Publicado: (2012)

Response to HER2 Inhibition in a Patient With Brain Metastasis With EGFR TKI Acquired Resistance and an HER2 Amplification
por: Meedendorp, Arenda D., et al.
Publicado: (2018)

HER2-/HER3-Targeting Antibody—Drug Conjugates for Treating Lung and Colorectal Cancers Resistant to EGFR Inhibitors
por: Yonesaka, Kimio
Publicado: (2021)

EGFR, HER2, and HER3 protein expression in paired primary tumor and lymph node metastasis of colorectal cancer
por: Ye, Peng, et al.
Publicado: (2022)

Polyclonal antibody-induced downregulation of HER1/EGFR and HER2 surpasses the effect of combinations of specific registered antibodies
por: Bergado-Báez, Gretchen, et al.
Publicado: (2022)

Antitumor activity of pan‐HER inhibitors in HER2‐positive gastric cancer
por: Yoshioka, Takahiro, et al.
Publicado: (2018)

Targeting EGFR/HER2/HER3 with a Three-in-One Aptamer-siRNA Chimera Confers Superior Activity against HER2(+) Breast Cancer
por: Yu, Xiaolin, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_20s559rici3fudthe7q1st4ift